These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28039480)

  • 21. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells.
    Glykofridis IE; Knol JC; Balk JA; Westland D; Pham TV; Piersma SR; Lougheed SM; Derakhshan S; Veen P; Rooimans MA; van Mil SE; Böttger F; Poddighe PJ; van de Beek I; Drost J; Zwartkruis FJ; de Menezes RX; Meijers-Heijboer HE; Houweling AC; Jimenez CR; Wolthuis RM
    Elife; 2021 Jan; 10():. PubMed ID: 33459596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases.
    Petit CS; Roczniak-Ferguson A; Ferguson SM
    J Cell Biol; 2013 Sep; 202(7):1107-22. PubMed ID: 24081491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.
    Tee AR; Pause A
    Fam Cancer; 2013 Sep; 12(3):367-72. PubMed ID: 23096221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of Birt-Hogg-Dubé syndrome implying reduced or no wild-type folliculin without mutated protein is pathogenic.
    Enomoto Y; Namba Y; Hoshika Y; Komemushi Y; Mitani K; Kume H; Kobayashi E; Miyama Y; Homma Y; Ushiku T; Seyama K
    Eur J Med Genet; 2020 Apr; 63(4):103820. PubMed ID: 31778855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
    Baba M; Furihata M; Hong SB; Tessarollo L; Haines DC; Southon E; Patel V; Igarashi P; Alvord WG; Leighty R; Yao M; Bernardo M; Ileva L; Choyke P; Warren MB; Zbar B; Linehan WM; Schmidt LS
    J Natl Cancer Inst; 2008 Jan; 100(2):140-54. PubMed ID: 18182616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique mutation, accelerated mTOR signaling and angiogenesis in the pulmonary cysts of Birt-Hogg-Dubé syndrome.
    Nishii T; Tanabe M; Tanaka R; Matsuzawa T; Okudela K; Nozawa A; Nakatani Y; Furuya M
    Pathol Int; 2013 Jan; 63(1):45-55. PubMed ID: 23356225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.
    Schneider M; Dinkelborg K; Xiao X; Chan-Smutko G; Hruska K; Huang D; Sagar P; Harisinghani M; Iliopoulos O
    Fam Cancer; 2018 Jan; 17(1):135-139. PubMed ID: 28623476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.
    Hasumi H; Hasumi Y; Baba M; Nishi H; Furuya M; Vocke CD; Lang M; Irie N; Esumi C; Merino MJ; Kawahara T; Isono Y; Makiyama K; Warner AC; Haines DC; Wei MH; Zbar B; Hagenau H; Feigenbaum L; Kondo K; Nakaigawa N; Yao M; Metwalli AR; Marston Linehan W; Schmidt LS
    Hum Mol Genet; 2017 Jan; 26(2):354-366. PubMed ID: 28007907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?
    Johannesma PC; Houweling AC; Menko FH; van de Beek I; Reinhard R; Gille JJ; van Waesberghe JT; Thunnissen E; Starink TM; Postmus PE; van Moorselaar RJ
    Fam Cancer; 2016 Apr; 15(2):297-300. PubMed ID: 26603437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.
    Dong L; Gao M; Hao WJ; Zheng XQ; Li YG; Li XL; Yu Y
    Medicine (Baltimore); 2016 May; 95(22):e3695. PubMed ID: 27258496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Birt-Hogg-Dube syndrome is a novel ciliopathy.
    Luijten MN; Basten SG; Claessens T; Vernooij M; Scott CL; Janssen R; Easton JA; Kamps MA; Vreeburg M; Broers JL; van Geel M; Menko FH; Harbottle RP; Nookala RK; Tee AR; Land SC; Giles RH; Coull BJ; van Steensel MA
    Hum Mol Genet; 2013 Nov; 22(21):4383-97. PubMed ID: 23784378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel FLCN Variant in a Suspected Birt-Hogg-Dubè Syndrome Patient.
    Bandini E; Zampiga V; Cangini I; Ravegnani M; Arcangeli V; Rossi T; Mammi I; Schiavi F; Zovato S; Falcini F; Calistri D; Danesi R
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of the Birt-Hogg-Dubé gene product folliculin induces longevity in a hypoxia-inducible factor-dependent manner.
    Gharbi H; Fabretti F; Bharill P; Rinschen MM; Brinkkötter S; Frommolt P; Burst V; Schermer B; Benzing T; Müller RU
    Aging Cell; 2013 Aug; 12(4):593-603. PubMed ID: 23566034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein.
    Laviolette LA; Mermoud J; Calvo IA; Olson N; Boukhali M; Steinlein OK; Roider E; Sattler EC; Huang D; Teh BT; Motamedi M; Haas W; Iliopoulos O
    Nat Commun; 2017 Jun; 8():15866. PubMed ID: 28656962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.
    Hasumi H; Baba M; Hasumi Y; Huang Y; Oh H; Hughes RM; Klein ME; Takikita S; Nagashima K; Schmidt LS; Linehan WM
    J Natl Cancer Inst; 2012 Nov; 104(22):1750-64. PubMed ID: 23150719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Birt-Hogg-Dubé tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis.
    Gaur K; Li J; Wang D; Dutta P; Yan SJ; Tsurumi A; Land H; Wu G; Li WX
    Hum Mol Genet; 2013 Jan; 22(2):284-99. PubMed ID: 23077212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of
    Liu L; Yang K; Wang X; Shi Z; Yang Y; Yuan Y; Guo T; Xiao X; Luo H
    Biomed Res Int; 2017; 2017():8751384. PubMed ID: 28785590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
    Hong SB; Oh H; Valera VA; Stull J; Ngo DT; Baba M; Merino MJ; Linehan WM; Schmidt LS
    Mol Cancer; 2010 Jun; 9():160. PubMed ID: 20573232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.